New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Andrew Leech

Dr Andrew Leech

Managing Paediatric Anxiety in General Practice

Prof Brendon Yee

Prof Brendon Yee

OSA – Which Test for Which Patient

Dr Sonia Davison

Dr Sonia Davison

Musculoskeletal Health in Menopause

Mr David Gardner

Mr David Gardner

AHPRA-Proof Your Practice – Social Media Risks for GPs

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970